Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women.

Alacacioglu, İNCİ; Ozcan, MA; Alacacioglu, A; Polat, M; Yuksel, F; DEMİRKAN, FATİH; Piskin, O; Ozgenc, Y; Ozsan, GÜNER; Undar, B

doi:10.1016/j.thromres.2004.05.012

Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women.

Atıf İçin Kopyala

Alacacioglu İ., Ozcan M., Alacacioglu A., Polat M., Yuksel F., DEMİRKAN F., ...Daha Fazla

Thrombosis research, cilt.114, sa.3, ss.155-9, 2004 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 114 Sayı: 3
Basım Tarihi: 2004
Doi Numarası: 10.1016/j.thromres.2004.05.012
Dergi Adı: Thrombosis research
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.155-9
Anahtar Kelimeler: preeclampsia, coagulation, fibrinolysis, thrombin activable fibrinolysis inhibitor, FETAL-GROWTH-RETARDATION, DEEP-VEIN THROMBOSIS, TAFI ANTIGEN, COAGULATION, MECHANISM
Dokuz Eylül Üniversitesi Adresli: Evet

Özet

To explain the pathogenesis of preeclampsia with coagulation induction or a defective fibrinolysis, various hemostatic parameters were studied and different treatment modalities targeting these parameters were evaluated. Considering the role of TAFI in down-regulation of fibrinolysis, in our study we have investigated whether TAFI contributes to impaired fibrinolysis in patient with preeclampsia.